Johnson & Johnson JNJ

$270.56 -2.64 (-0.97%)

Valuation

Market cap
657,677,120,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.84
P/E (forward)
24.76
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,262,900
Avg volume
7,013,432
Day's range
$267.43 – $273.01
Shares out
2,407,310,000
Stochastic %K
58%
Beta
0.21
Analysts
Moderate Buy
Price target
$281.88

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Netlinetli Nov 3, 4:00 PM
$ICU $BAX $MCK $JNJ $MRNA so how can you explain there are no investors? Bleeding everyday since big announcemnt on important conference? All those guys who are rich AF , doctors, people from pharma business etc. They have plenty of money, they know the „news” and understand the potential of medical devices better than anyone. Why they dont give a f** about this company ???
1 replies
SparkyReturns Nov 3, 3:50 PM
$ICU Sitting at a mere 10M Market Cap, Seastar (ICU) will generate more revenue than that in 2027 with today's removal of the registry requirement. 7 BDDs, with the most recent for Sepsis as a standalone indication. TAM easily in the billions once adult use approved in early/mid-2027. Pediatric already approved under HDE. Incredibly underpriced. Related biotechs that supply tubing, equipment, and medicines for Sepsis, AKI, cancer, and heart disease could also be affected. https://investors.seastarmedical.com/news-releases/news-release-details/fda-confirms-seastar-medical-has-fulfilled-post-approval-study $BAX $MCK $JNJ $MRNA
0 replies
Stocktradesmoon Nov 3, 2:41 PM
$ABCL $MRNA $REGN $SLS $JNJ Now everyone is finding themselves chasing… All those sellers are now buying it up. Earnings coming up in a few days …November 9th Follow by 2 huge biotech conferences that they will be presenting at. November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. 👀
0 replies
SellasgpsCurativeBAT11 Nov 3, 12:51 PM
$SLS $RVMD $MRNA $JNJ Sellas GPS Regal Pivotal Registrational Phase 3 study Paradigm Shifting success = $120.00+ before BO because it’s the master key to 20+ other WT1 cancers. ✌️🙏❤️‍🩹
1 replies
Quantumup Nov 3, 12:18 PM
JPMorgan🏁 $TRXB and said--We are initiating coverage of TRexBio (TRXB) with an OW rating and a Dec- 2027 PT of $20. [ $JNJ $LLY [ABBV SNY - REGN PFE CRVS QTTB MANE NKTR CLDX Dren Bio, ALYS Pharma, Legacy Healthcare, Reistone, Suzhou, EVMN KYMR BCRX ACRX]] JPMorgan went on to say: https://x.com/Quantumup1/status/2117591895756931124?a=mNmaGRo8llaCqVgmZyQ&s=20
0 replies
SellasgpsCurativeBAT11 Nov 3, 12:17 PM
$SLS $MRNA $RVMD $JNJ Sellas SSR in effect going in to Major Catalysts in Sellas Corporate history. 20,000 HTB shares available to short. 👇 ✌️🙏❤️‍🩹
2 replies
GlobalTradersAcademy Nov 3, 7:06 AM
Off-exchange trading in $JNJ was above normal at about 1.3x. The full read shows the session-by-session dark pool share and which institutions are adding or cutting. The full dark-pool read, with the options side: https://globaltradersacademy.com/articles/dark-pool-activity-what-big-money-did-in-johnson-johnson-jnj-off-the-exchanges?utm_source=stocktwits&utm_medium=social
0 replies
topstockalerts Nov 3, 1:21 AM
During CNBC’s Mad Money Lightning Round, Jim Cramer offered mixed views on several stocks amid the ongoing technology-sector selloff. He strongly recommended buying Howmet Aerospace, noting that the stock has pulled back considerably despite the company continuing to deliver solid financial results, making the recent weakness an attractive buying opportunity. Cramer also remained bullish on Johnson & Johnson, arguing that the company has further upside potential as it moves away from lower-multiple, commodity-based synthetic joint products in its orthopedics business, allowing investors to focus on its more attractive growth opportunities. He instead highlighted Lam Research, trading at approximately 23 times earnings, as his preferred name in the group. Finally, Cramer acknowledged that Western Digital is a good company but said he considers Micron a stronger investment opportunity, reflecting his preference for its competitive positioning in the memory market. $HWM $JNJ $WDC $MU
1 replies